Wednesday, 14 December 2016

Global Hypertrophic Cardiomyopathy Therapeutics Market to Witness Sluggish Growth; to Register 1.4% CAGR 2015-2023

Hypertrophic Cardiomyopathy (HCM) is a common disease of the heart muscles where the thickening of the myocardium results in functional impairment. HCM is a genetic condition affected by mutation in genes. As per the European Society of Cardiology, the occurrence of HCM in 2013 was between 0.05% and 0.2% of the population. According to a study presented by BioMed Central in 2010, there was no specific age and gender differences in the occurrence of HCM. The occurrence of HCM is reportedly the highest among African-Americans.
These factors have paved the way for the growth of the global hypertrophic cardiomyopathy therapeutics market. It is expected to register a steady CAGR of 1.40% between 2015 and 2023, states a new report published by Transparency Market Research. At this CAGR, the global hypertrophic cardiomyopathy therapeutics market is expected to reach US$1.4 bn by 2023.
Global Hypertrophic Cardiomyopathy Therapeutics Market – Key Trends
With heart diseases emerging as one of the most common causes of mortality among men and women worldwide, Transparency Market Research (TMR) expects the demand for hypertrophic cardiomyopathy (HCM) therapeutics to surge considerably. Furthermore, the market is expected to gain significant impetus from successful government interventions aimed at spreading awareness about hypertrophic cardiomyopathy.
TMR projects the global HCM therapeutics market to expand at a moderate 1.4% CAGR between 2015 and 2023. Despite witnessing positive opportunities, the rising demand for advanced medical devices could threaten the market’s growth to an extent. Nevertheless, since the majority of HCM drugs are yet to get approved, the hypertrophic cardiomyopathy therapeutics market is likely to gain momentum post their approval in the near future.
According to TMR, the global hypertrophic cardiomyopathy therapeutics market is expected to reach US$1.37 bn in 2023, from US$1.2 bn in 2015. The leading players in the market are likely to capitalize on the untapped opportunities in the healthcare sector of emerging economies to expand their footprint.
Rising Penetration of Advanced Medical Devices to Threaten Market Growth
Despite witnessing positive growth opportunities, the rising penetration of medical devices such as pacemakers and defibrillators in the healthcare sector has been inhibiting the HCM therapeutics market’s trajectory. Demand for gene therapy and implantable medical devices is rising as patients gain adequate knowledge about positive results offered by such advanced medical devices. The increasing acceptance of these medical devices could limit the scope of expansion for the HCM therapeutics market.
Nevertheless, drugs created specifically for the treatment of hypertrophic cardiomyopathy are yet to find approval. Once approved, this indication will bolster sales opportunities for the market players. Additionally, due to the high prevalence of unmet medical needs across Asia Pacific and the increasing medical expenditure in the region also boosts prospects for the HCM therapeutics market.
Regionally, North America holds the largest share in the global HCM therapeutics market. However, as per TMR, the market is also expected to witness strong growth in Asia Pacific and Rest of the World. The Asia Pacific HCM therapeutics market is poised to expand at 2.9% CAGR between 2015 and 2023. By drug class, the market was led by calcium channel blockers in 2014. By drug class, the calcium channel blockers is expected to dominate the market. It held over 37.4% of the HCM therapeutics market in 2014.
TMR estimates the overall value of the global hypertrophic cardiomyopathy therapeutics market at US$1.2 bn in 2014. Exhibiting a moderate CAGR of 1.4% from 2015 to 2023, the market is expected to reach US$1.3 bn by the end of 2023.
Posted by at No comments:
Labels: , ,

Thursday, 8 December 2016

Global Expression Proteomics Market: Major market share is commanded by prokaryotic segment

Expression proteomics includes the study of the dysregulated proteins as a function of stimulation or patient condition. The patient condition depends on the disease or specific drugs related to any disease. The market for expression proteomics is segmented into four major categories, on the basis of applications, by expression system, by products and by the End users. By expression system, market of expression proteomics consists of four segments including:
  • Mammalian
  • Prokaryotes
  • Baculovirus
  • Yeast
Among the expression system segments, the major market share is commanded by prokaryotic segment. The use of Escherichia Coli (E.Coli) is mostly preferred as a host cell due to its easy availability and cheap protein expression and production. Mammalian segment is also showing increased growth as demand for therapeutic proteins has increased leading to need for proteins with post-translational modification and increasing use of mammalian expression systems.
The market for expression proteomics on the basis of the product is differentiated into four major segments which include:
  • Competent Cells
  • Expression vectors
  • Instruments
  • Reagents
In the product segment for expression proteomics market, reagents is the major revenue generating product driven by the demand of immunoassays, microarray reagents and spectroscopy reagents. These reagents are easy to use and are less expensive comparatively and therefore, used in large number for transfection and maintenance of cell lines. Instruments are further divided into six major categories according to the techniques involved in expression proteomics namely microarrays, mass spectrometers, NMR spectrometers, chromatography, electrophoresis, surface plasmon resonance and X-ray crystallography. Among these protein microarrays are dominating the market followed by spectroscopy technique.
On the basis of application of expression proteomics, the market is divided into three segments including:
  • Industrial proteins
  • Research applications
  • Therapeutic proteins
Among these segments, therapeutic proteins are dominating the market for expression proteomics due to its versatile advantage over other small molecule drugs to alleviate diseases. On the basis of end users, the market is majorly classified into three parts namely pharmaceutical, biotechnology and research organizations.
The market for expression proteomics is growing at faster pace majorly driven by the globally increasing intensity in research in the pharmaceutical and biological sector. Additionally, the factors such as increased demand for personalized medicine, technological advancement and increasing use of proteomic outcomes in diagnosis and drug discovery also propels the market growth. However, reduction in funding towards sequestration cuts in U.S., high cost of expression proteomics tools, difficulty in gaining regulatory approvals and dearth of qualified researchers are some of the factors which are restraining the growth of this market to some extent.
North America currently leads the global market for expression proteomics followed by Europe. The major factors driving the expression proteomics market in these regions are the technological advancements and rising demand for the expression proteomics in personalized medicines. The expression proteomics market in Asia-Pacific is also showing rapid growth due to increasing government and private funding towards research and development in countries such as Japan, India, Australia and China. The major key players in the expression proteomics market include ActivX Biosciences, Inc, Agilent Technologies, Inc., Life Technologies Corporation, New England Biolabs, Inc., QIAGEN, Takara Bio, Inc., Bio-Rad Laboratories, Merck Millipore, Hybrigenics SA , Tyrian Diagnostics, Ltd, Luminex Corporation, Promega Corporation, Danaher Corporation , Caprion Proteomics, Inc Sigma-Aldrich Corporation and Thermo Fischer Scientific, Inc.
Posted by at No comments:
Labels: , , , ,

Genotype Analysis Market to 2019: Trends, Business Strategies and Opportunities with Key Players Analysis

An individual’s genetic makeup is determined by DNA sequences comprising varied combinations of nucleotides namely, adenine, thymine, cytosine, and guanine. Alterations of the genetic code and consequent undesirable traits or disease conditions can occur due to variation in these DNA sequences. Genotyping helps determine differences in the individual’s genetic makeup wherein the individuals DNA sequence is examined using biological assays and is compared to another individuals DNA sequence or a reference sequence. Genotyping analysis plays an important role in research of genes and gene variants associated with disease. Single nucleotide polymorphisms (SNPs) are the most common form of variation which occurs on change in single nucleotide in the genome sequence. SNP genotyping is rapidly growing as a useful tool in many scientific disciplines including personalized medicine, plant and animal biotechnology.
The various methods used for genotyping analysis include polymerase chain reaction (PCR), amplified fragment length polymorphism detection (AFLPD), random amplified polymorphic detection (RAPD) of genomic DNA, allele specific oligonucleotide (ASO) probes, DNA sequencing, restriction fragment length polymorphism identification (RFLPI) of genomic DNA, and hybridization to DNA microarrays or beads. Genotyping can be applied to humans as well as microorganisms. Genotyping of viruses or bacteria may help in tracing the origin of outbreak and thus control the spread of pathogens. Genotyping develops and provides innovative technologies that enable multiplex and parallel analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of results into biology for a better world. Genotyping researchers face major challenge in studying rare variants most effectively. Whole-genome sequencing is preferred by some for studying rare variants, however often it is too slow and too expensive while microarrays are more cost-effective and allow for higher-throughput.
The global genotyping analysis services market is segmented based on various services provided by the key players. These companies provide diverse portfolio of genotyping analysis service offerings such as human whole genome sequencing services, microarray services, long read sequencing services, certified service provider program and other services such as core lab program, service partnerships, analysis and data management solutions as custom array service, whole genome services and genome-wide genotyping services. Growing demand from pharmacogenomics, diagnostic research and animal breeding are some of the factors driving the market growth. Developing as well as developed countries are expected to witness increasing demand for genotyping services that are within the reach of a common man, since people want to understand their genetic make-up in terms of aesthetic awareness in terms of height, weight, obesity or for diseases such as diabetes, cancer, cardiovascular and others.
Rising interest in personalized genomic analysis and growing thrust for using rapidly increasing knowledge regarding individual genetic variations to personalize diagnosis as well as treatment is also responsible for driving the growth of the market. However, this direct to consumer model for providing genetic analysis directly to an individual has been posing a problem due to concerns from FDA regulatory agencies about providing health care information directly to non-professionals. Healthcare providers may make it a general practice for routine DNA sequencing on patients thus making it needless for individuals to initiate it themselves.
On the other hand, technological limitation has been a major constrain to the growth of global genotyping analysis services market which leads to determination of only small fraction of an individual’s genotype. Moreover, issues involving intellectual property and ethics will need to be addressed before personalized medicine can become a true reality.
Some of the key service providers in global genotyping analysis market include Affymetrix, Illumina, Harlan Laboratories, Fluidigm, Life Technologies, Sequenome and Roche Diagnostics.
Posted by at No comments:
Labels: , ,

Bioremediation Technologies Market - Global Industry Analysis, Trends and Forecast, 2013 - 2019

Bioremediation is a scientific waste management process that uses various, fungi, microorganisms, green plants and their enzymes to reinstate the environment to its original state after removing pollutants from a contaminated site. Bioremediation of water and soil, which is polluted by oil and other industrial waste; is performed by a variety of microorganisms that survive on hydrocarbons. Degradation of pollutants by bacterial microorganisms breaks down the hazardous substances into less toxic biodegradable substances. However, not all pollutants and contaminants are treated by bioremediation using microorganisms. For example, metals such as lead and cadmium are not easily captured or absorbed by microorganisms.
The overall bioremediation technologies and services market is expected to witness an admirable growth due to the increasing awareness for environmental safety and protection. Moreover, stringent government regulations and policies for environmental restoration initiatives is further fuelling the popularity of biotechnology based bioremediation technologies and services globally. Furthermore, novel bioremediation technologies such as bioaugmentation and biostimulation are gaining wide acceptance and interest due to their enhanced environmental restoration capabilities. These technologies use nutrient additives and external microbial agents for remediation of huge amounts of hydrocarbon-contaminated liquids and soil. Additionally, potential technological breakthroughs will generate abundant opportunities for bioremediation technologies and services.
Some of the bioremediation technologies usually used for reinstating and de-contamination the environment are as follows:
  • Biostimulation
  • Bioaugmentation
  • Air Sparging
  • Bioventing
  • Bioslurping
  • Fungal Remediation
  • Phytoremediation
  • Nitroaromatics
Various bioremediation services used for restoring our environment are as follows:
  • Sample collection and analysis
  • Manufacture of site-specific bioremediation products
  • Design of optimized bioremediation program
  • Characterization and spill evaluation of environmental parameters
  • Report results
  • Field services
In the geographical analysis, North America closely followed by Europe is the largest market for bioremediation technologies and services owing to the stringent environmental protection policies and regulations as well as oil spill accidents. For instance, a recent oil spill accident happened in the city of Los Angeles witnessed an oil spill of nearly 50,000 gallons which had ultimately contaminated the soil. These industrial hazards, which occur frequently across the globe, are expected to propel the sales of bioremediation technologies and services in these regions. Moreover, strict orders and policies from environmental protection agencies and groups are also compelling various industrial units to treat their waste products before releasing it in the environment. However, other regions such as South East Asia, Latin America and Middle East are expected to be the potential markets in the near future. Due to the increase in industrial plants and stringent environment safety concerns, these regions are expected to be the potential markets in the near future .
Other factors such as frequent oil spills in oceans from oil tankers are compelling oil and gas companies to adopt bioremediation technologies as well as services to restore the environment to its original state. However, high development cost and low adoption rate among population are some of the market-restraining factors that might hinder the growth of the overall bioremediation technologies and services market.
At present, the bioremediation technologies and services market is highly fragmented owing to the involvement of many established and emerging players in this industry. However, the key players involved with the development of bioremediation technologies and services are ABB Environmental Services, Inc., Altogen Labs, Bioremediation Service, Inc., Dow Chemical Company, EG&G, Inc., E. I. du Pont de Nemours and Company, Envirogen Technologies, General Electric and Sevenson Environmental Services, Inc.
Posted by at No comments:
Labels: , ,

Wednesday, 7 December 2016

Microbiology Culture Market to Reach US$7.59 bn by 2023 due to Increasing Life Science Research Funding Globally

The soaring demand for antibiotics, on account of the alarming rise in the prevalence of various infections and food-borne diseases, has provided a significant thrust to microbiology culture practices across the world over the last few years. According to the Centers for Disease Control and Prevention (CDC), in the U.S. alone, a total of 23.6 million cases of infectious and parasitic diseases were reported in 2010. Since microbiology culture is an efficient diagnosis method to detect the cause of a number of infectious diseases, its application in the production of antibiotic drugs is witnessing a remarkable rise, worldwide.
The consumption of antibiotics is also experiencing a sturdy growth in the BRICS nation. A 2014 report by Lancet Infectious Diseases Commission stated that the consumption of antibiotic drugs increased globally by 36% from 2000 to 2010, wherein BRICS countries accounted for a share of 76% of this growth. All these factors, together, point towards an opportunity-rich future for the worldwide market for microbiology culture over the coming years.
The global market is projected to witness an increase in its opportunity from US$4.5 bn in 2014 to US$7.5 bn in 2023, expanding at a CAGR of 5.90% during the period from 2015 to 2023. The advent of food microbiology, the rise in concerns over food safety, and the increase in the government funding in life science research are some of the other factors expected to drive the global microbiology culture market in the near future.
North America to Retain Dominance in Terms of Revenue
On the basis of region, the global microbiology culture market is segmented into Asia Pacific, Europe, North America, Latin America, the Middle East, and the Rest of the World. North America emerged as the leading regional market in 2014 with a revenue of US$1.6 bn. The presence of a large pool of biopharmaceutical firms and research institutes played a significant role in driving the market for microbiology culture in North America.
Analysts expect this region to retain its lead over the forecast period. However, Asia Pacific is likely to present the most promising opportunities and register the fastest CAGR of 6.80% from 2015 to 2023. The unmet medical needs of people, coupled with the growing prevalence of infectious diseases, the surge in the healthcare expenditure, the rising focus on food safety, and the increasing demand for antibiotics, are likely to provide an opportunity-rich market for participants in the near future.
Complex Media to Remain Most-preferred Culture Media
Complex media, special media, simple media, and synthetic media are the main culture media utilized in microbial culture. Among these, complex media emerged as the most preferred media for microbiology culture in 2014 and was closely followed by special media. As per estimations, complex media will remain the preferred culture media throughout the forecast period as it caters to a wide range of requirements important for the cultivation of nutritionally complex or kinds of unknown bacteria.
The global market for microbiology culture is led by Sigma-Aldrich Co. LLC, Merck Millipore, Thermo Fisher Scientific Inc., and Becton, Dickinson and Co. In 2014, these four players collectively accounted for a share of more than 50% in the overall market. Some of the other prominent players are BioMérieux SA, Bio-Rad Laboratories, Hi-Media Laboratories Pvt. Ltd., Eiken Chemical Co. Ltd., Scharlab S.L., and Neogen Corp.
Posted by at No comments:
Labels: , , ,

Epileptic Anticonvulsants Market - A Booming trend in Healthcare Analytics Industry

According to the WHO, nearly 80% of epilepsy patients are found in developing regions. However, developed regions are dominant in the global epileptic anticonvulsants market. Currently, North America dominates the epileptic anticonvulsants market, followed by Europe. Highly developed healthcare infrastructure, high level of awareness, high healthcare spending on epilepsy and related treatments, along with availability of skilled professionals to treat epilepsy are driving the North America and Europe epileptic anticonvulsants markets.
The report on the global epileptic anticonvulsants market delivers a snapshot of the key market drivers, restraints, and opportunities. In addition, market forecasts with other statistical data will help key businesses and new entrants in the market to scrutinize the feasibility of the market. Backed by in-depth primary and secondary research, the report on the epileptic anticonvulsants market is an invaluable tool for enterprises in the market.
Overview of the global epileptic anticonvulsants market
Epilepsy is a chronic noncommunicable condition of the brain which can affect people of all ages. It leads to repeated and unprovoked seizures (convulsions). Anticonvulsants are used primarily to treat epileptic seizures. Epileptic anticonvulsants are also used for neuropathic pain management and treatment of bipolar disorder. Some of the symptoms noticed in a patient before the convulsion occur are visual loss, nausea, strange feeling, headache, numbness in body parts, and racing thoughts.
Some of the drivers of the epileptic anticonvulsants market include growing awareness of the availability of anticonvulsants in the market and patent expiration of many patented drugs. On the other hand, convenient dosage and cost advantage of currently available generic epileptic anticonvulsants are inhibiting the growth of novel therapies in the market. The global epileptic anticonvulsants market is segmented on the basis of the use of epileptic anticonvulsants according to the disorder, type of drugs, and geography.
Even though North America is leading the market, Asia Pacific promises swift growth in the epileptic anticonvulsants market. This is attributed to the growth of the medical tourism industry in Asia-Pacific countries such as China, India, and Japan. Heavy investment and involvement of the Japanese government to enhance infrastructure will boost the Asia-Pacific epileptic anticonvulsants market. Many Latin American countries such as Argentina, Brazil, and Mexico will demonstrate good growth potential in the epileptic anticonvulsants market.
Companies mentioned in the research report
A detailed profile of the top key players is presented in the report. Some of the key corporations in the epileptic anticonvulsants market include Novartis AG, Johnson & Johnson (J&J), UCB Group, Abbot Laboratories, Pfizer Inc., and GlaxoSmithKline plc.
Posted by at No comments:
Labels: , , ,

Global Medical Image Analysis Software Market: Asia Pacific to Present Most Promising Growth Opportunities, Says TMR

As per a new research report by Transparency market Research (TMR), the global medical image analysis software is expected to gain a substantial momentum in the next few years. The study, titled “Medical Image Analysis Software Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015–2023,” further states that the consistent technological advancements and the rising demand for platform independent, n-dimensional image processing and visualization are the key factors behind the phenomenal growth of this market.
According to the study, the escalating demand for diagnostic procedures, together with continual innovation and reliable support for the development of this software is projected to drive this market remarkably throughout the forecast period. However, the dearth of knowledge about the usage of medical image analysis software among consumers and the high cost associated with it may create obstructions in the growth trajectory of this market in the coming years, states the research report.
In this research study, the global medical image analysis software market has been analyzed on three fronts: The imaging modality, end user, and the geography. Based on the imaging modality, the market has been classified into positron emission tomography and single photon emission computed tomography, computed tomography, magnetic resonance imaging, microscopy, ultrasound, and X-ray. Based on the end user, the market has been categorized diagnostic centers and general hospitals.
Geographically, North America, Asia Pacific, Europe, and the Rest of the World have been identified as the key segments of the worldwide market for medical image analysis software. Among these, Asia Pacific has surfaced as the leading regional market on account of the increasing prevalence of life-threatening diseases and medical conditions. Researchers expect the scenario to remain same over the period of forecast, notes the market study.
The competitive landscape of the worldwide market for medical image analysis software has also been assessed in this research report. Researchers have thoroughly reviewed the profiles of the key players and have also studied the historical performance future prospects of each of participants in order to determine the present hierarchy in this market. The leading developers of medical image analysis software mostly rely on product innovation and advancements in technologies for sustenance. They have also begun to focus on partnerships, mergers, and acquisitions to expand their businesses across geographies.
Some of the prominent enterprises in the global market for medical image analysis software are GE Healthcare, Agfa Healthcare, Philips, Spacelabs Healthcare, Xinapse Systems Ltd., EsaoteSpA, Claron Technologies, Toshiba Medical Systems, and Siemens AG, states the research report.
Posted by at No comments:
Labels: , ,
Subscribe to: Posts (Atom)